Business
iBio Reports Fiscal Third Quarter 2025 Financial Results
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of
About this update from Ibio, Inc.
[{"type":"image","alt":"iBio, Inc.","displaySize":"","headline":null,"caption":"iBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SJdaoYV8WWMD9fxupwqycw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac","width":300,"height":170}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.","length":195,"tagName":"p"},{"type":"text","content":"“During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026,” said Martin Brenner, Ph.D., DVM, iBio’s Chief Executive Officer and Chief Scientific Officer. “At the same time, we made significant strides in our pipeline, with promising non-human primate data for IBIO-600 and the in-licensing of a first-in-class Activin E antibody, two antibodies we truly believe are bringing us closer to fulfilling our mission of delivering transformative therapies to patients suffering from cardiometabolic diseases and obesity.”","length":788,"tagName":"p"},{"type":"text","content":"Fiscal Third Quarter 2025 & Recent Corporate Updates: ","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Began trading on the Nasdaq Stock Exchange under the ticker symbol “IBIO,” marking a significant corporate milestone that enhances visibility, improves trading liquidity, and aligns with the company’s strategy to attract long-term institutional investors.","length":255,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported non-human primate data for IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, demonstrating extended half-life and dose dependent muscle growth. Simultaneously, iBio announced...